All News
Sex Differences in Autoimmune Disease Susceptibility: Drs. Yusof and Robinson
Dr. Yusof interviews Dr. Robinson about abstract OP0013 presented at the virtual #EULAR2021 meeting.
https://t.co/IPe6lMM7NQ https://t.co/Dt36N3OhZg
Links:
Dr. John Cush RheumNow ( View Tweet)
RheumNow’s expanded coverage of the #EULAR2021 Annual meeting is sponsored in part by Novartis, Bristol Myers Squibb, & Janssen. All content chosen by RheumNow & its Faculty.
Dr. John Cush RheumNow ( View Tweet)
DANBIO + Swedish register SGR linked to national birth registers (matched 1:10): RA-pregnancies: higher preterm birth (OR 1.92, 95CI 1.56-2.35) and small gestational age (OR 1.93, 95CI 1.45-2.57). Association strengthened by high disease activity.
#OP0210 @Rheumnow #EULAR2021 https://t.co/Fjm0uxCPgC
Aurelie Najm AurelieRheumo ( View Tweet)
KEEPsAKE 2: Risankizumab RCT in Bio-IR or csDMARD-IR active PsA. Primary endpoint ACR20 W24 met with 51.3% vs 26.5% in PBO group (P < .001) and ACR50 26.3% vs 9.3%. No particular safety signal.
#OP0228 @Rheumnow #EULAR2021 https://t.co/HZv8qoc4sz
Aurelie Najm AurelieRheumo ( View Tweet)
What is the impact of RA on fertility in men:
#OP0211 and #OP0212 @Rheumnow #EULAR2021
Aurelie Najm AurelieRheumo ( View Tweet)
COSMOS study: Guselkumab RCT in PsA pts TNFi-resistants (1 or 2) 44.4% of GUS vs 19.8% of PBO pts achieved ACR20 at w24 (p<0.001) and GUS > PBO for most secondary endpoints. Tolerance: 18% vs. 20% infections/SI.
#OP0230 @Rheumnow #EULAR2021 @DrLauraCoates https://t.co/fFle2OR8KM
Aurelie Najm AurelieRheumo ( View Tweet)
Retrospective RA cohort study: overall risk of dementia ⬆️ in RA (HR 1.38; 95%CI 1.04-1.83) BUT 10-year cumulative incidence of dementia ⬇️:
12.7% in 1980s
7.2% in 1990s
2000s 6.2% Risk no longer significantly ⬆️ for patients w/ RA onset in 2000s! @RheumNow #EULAR2021 #OP0216 https://t.co/TVRTTJjvno
Aurelie Najm AurelieRheumo ( View Tweet)
Serious infections and BioDMARDs: what is the confounding factor?
BSRBR-RA: 33,916 RA treated w/ BioDMARDs with 62,532 years of follow-up, 2036 SI. HR of SI no longer different among BioDMARDs when adjusted for the line of therapy! #OP0241@Rheumnow #EULAR2021 https://t.co/UG9WrXP7RD
Aurelie Najm AurelieRheumo ( View Tweet)
COVID-19 Global Rheum Alliance Registry: prediction of ARDS by machine learning algorithm in a model using 42 variables including:
demographics, rheumatic D, meds and comorb with Sens 0.81, Spe 0.49, AUC 075. Interesting model for close monitoring #OP0288 @Rheumnow #EULAR2021 https://t.co/9YY0jzDx59
Aurelie Najm AurelieRheumo ( View Tweet)
PreCARA: analysis of cord blood levels of TNFi in RA pregnancy:
-CTZ n=68 measured in 5.9% and low concentrations
-ETA n=28 not detected
-ADA n=24 in 50% low C
-INF n=13 in 61.5% low C
for both even in patients who discontinued at GA 20 weeks.
@RheumNow #EULAR2021 #POS0202 https://t.co/osBrmbepkb
Aurelie Najm AurelieRheumo ( View Tweet)
D2T RA is definitely a complex disease interlinked w/ multimorbidity
@ElenaNikiUK reminds us of the importance of:
1) Detecting comorbidities
2) Adress multimorbidity
to 3) Provide patient-centred care tailored to their specific needs #EULAR2021 @RheumNow https://t.co/ebyYDqnQ1k
Aurelie Najm AurelieRheumo ( View Tweet)
RA: total comorbidity count ≤1 (vs ≥ 2) predicts LDA/Rem @6 months ttmt [OR 4.1 p=0.005], while RDCI=0 (vs. ≥ 1) predicts HAQ improvement ≥0.25 [OR 2.6 p=0.046] Basal predictors of D2TRA: RDCI≥ 1(vs. 0) [OR 3.3 -p = 0.024], female sex and age
#OP02999 @Rheumnow #EULAR2021 https://t.co/wc16oCKcix
Aurelie Najm AurelieRheumo ( View Tweet)
#EULAR2021 key note speaker, Mark Pollock, is a model of resiliency after blindness and later, a spinal cord injury. "Sometimes we have the luxury of choosing our challenges and sometimes the challenges choose us." @RheumNow
Dr. Rachel Tate uptoTate ( View Tweet)
Poster from Cohen et al #POS0220 at #EULAR2021 No new safety signals in UPA treated RA patients in 4.5 years of SELECT clinical trial data. @RheumNow https://t.co/Q48ZaUee8q
Dr. Rachel Tate uptoTate ( View Tweet)
ASTERA phase 3 analysis: NTK leads to decline of disease activity in AS pts irrespectively of sacroiliitis on MRI. Abstract #OP0142 #EULAR2021 @RheumNow https://t.co/51f18728ZB https://t.co/qZcsMlKqbW
Links:
Dr. Rachel Tate uptoTate ( View Tweet)
Real world data from German AQUILA: SEC improved PsA dz activity in M & F pts. Female pts had higher dz burden prior to tx. #EULAR2021 Poster #POS0123 @RheumNow https://t.co/cNIN6yqN0j https://t.co/nPZLDztxQP
Dr. Rachel Tate uptoTate ( View Tweet)
Phase 2 Deucravacitinib, oral, selective TYK2i results: Analyses confirmed the efficacy of deucravacitinib vs PBO across TNFi & body weight subgroups. Safety profile similar to that found in PsO trials. Abstract #OP0227 #EULAR2021 @RheumNow https://t.co/BBvn5MaXPp https://t.co/jWFhpmkuC5
Links:
Dr. Rachel Tate uptoTate ( View Tweet)
KEEPsAKE 2 results: RZB showed greater improvements in signs & symptoms of PsA vs PBO, met all primary/secondary endpoints, & was well tolerated in Bio-IR or csDMARD-IR pts. Safety profile consistent w/ PsO trials. Abstract #OP0228 #EULAR2021 @RheumNow https://t.co/jsF2JVTupg https://t.co/oiZWZ7Pkf2
Dr. Rachel Tate uptoTate ( View Tweet)
GRAPPA 2021 treatment update highlights!
▶️Domain-specific tx choices
▶️Uveitis & IBD added
▶️ IL17i, IL23i, & JAKi strongly recommended in multiple domains
▶️PDE4i recs for dactylitis, enthesitis, & nail PsO
▶️Against IL6i
#OP0229 #EULAR2021 @RheumNow https://t.co/5KFQu7myPO https://t.co/R9YSZBwFDh
Dr. Rachel Tate uptoTate ( View Tweet)
COSMOS study results: GUS 100 mg Q8W showed ⬆️ACR20 vs PBO at W24; results of prespecified sensitivity and subgroup analyses were consistent. Safety profile consistent with PsO & biologic-naïve PsA pts. Abstract #OP0230 #EULAR2021 @RheumNow https://t.co/CFN1MHB9yv https://t.co/BOZqyqaHPe
Links:
Dr. Rachel Tate uptoTate ( View Tweet)
